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In this study the question was addressed whether cAMP
mediated drugs induce a differential reduction of branches
of the arachidonic acid metabolism rather than a global
reduction of eicosanoid synthesis. The isolated lungs of
actively sensitized rats were employed to study prostaglan-
din and leukotriene release in the presence and absence
of the cAMP mediated drugs theophylline, milrinone,
sulmazole, isobutyl-methylxanthine and salbutamol. The
release of eicosanoids as measured by RIA was predo-
minantly basal and continuous, with a mild antigen in-
duced stimulation only for TXB2 and the leukotrienes. All
drugs reduced eicosanoid release globally. It is concluded
that cAMP mediated drugs interfere with arachidonic acid
metabolism at a site proximal to the branching into lipox-
ygenase and cyclo-oxygenase pathways.
Key words: AA 861, cAMP, l,eukotrienes, l,ung, Milrinone,
Prostaglandins
Cyclic-AMP mediated drugs"
differential or global reduction
of eicosanoid synthesis in the
isolated rat lung?
Mark J. Post,*’cA Jan Dirk te Biesebeek,
Johan Wemer,* Hans H. van Rooij,
Freek J. Zijlstra and Arijan J. Porsius
Department of Pharmacotherapy, Faculty of
Pharmacy, P.O. Box 80082, 3508 TB University
of Utrecht, Utrecht, The Netherlands;
1Department of Pharmacology, Erasmus
University, P.O. Box 1738, 3000 DR Rotterdam,
The Netherlands
*Present address: Laboratory for Experimental
Cardiology, Department of Cardiology, University
Hospital Utrecht HPN E 02.562, P.O. Box 85500,
3508 GA Utrecht, The Netherlands
ca Corresponding Author
Introduction
Drugs that reduce eicosanoid synthesis might be
valuable in symptomatic and curative therapy of
various inflammatory diseases. Such drugs include
cAMP elevating compounds like the xanthine
derivatives theophylline and IBMX, and
sympaticomimetic drugs and inhibitors of cyclic
nucleotide phosphodiesterase isoenzymes. 1’2 Milri-
none and sulmazole are two recently developed
cardiotonic and vasodilator drugs that belong to the
latter category.’4 In previous experiments we
compared the effects of milrinone, sulmazole and
theophylline in the rat isolated lung. We showed
that these drugs inhibited antigen induced broncho-
constriction, vasoconstriction and SRS-A release,
leaving the release of the preformed mediators
histamine and serotonin unaffected. Rossing et al.
also showed a bronchorelaxant effect of milrinone
against a variety of agonists in trachea, lung
parenchyma and pulmonary artery, that could be
counteracted by indomethacin.
6 This led them to
hypothesize that milrinone exerted a differential
effect on arachidonic acid metabolism and either
induced the synthesis of bronchorelaxing prosta-
glandins or reduced indomethacin enhanced pro-
duction of bronchoconstrictive leukotrienes. In this
study we addressed the question of whether cAMP
mediated drugs induce a differential reduction of
branches of the arachidonic acid metabolism rather
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than a global reduction of eicosanoid synthesis. We
incorporated AA 861 in the study as a selective
inhibitor of leukotriene synthesis7’8 to check
whether selective modulation of arachidonic acid
metabolism could be shown in our model.
Materials and Methods
Sensitization: Male Wistar rats, weighing 180-200 g,
were actively sensitized. For this purpose, an
emulsion was made of trinitrophenylovalbumin in
aluminium phosphate, containing 50 #g ml-1 TNP-
OVA and 6mg/mlA1PO4. Of this solution,
2 ml was injected intraperitoneally. After 12-21
days the animals were used for experiments.
Rat isolated and ventilated lungs with vascular perfusion:
Lungs were removed under pentobarbitone-Na
anaesthesia (50mgkg-li.p.), suspended in a
Plexiglas chamber and perfused through the
pulmonary artery with Krebs-Ringer solution
(37C and gassed with 5% CO2 in O2) at a rate of
7.5 ml min -1. The lungs were ventilated (25 min-)
with a Braun piston pump by applying vacuum
within the surrounding chamber, alternating from
-6.5 cm H20 to --1 cm H20. A constant flow
of O2 with 5% COg into the trachea imposed a
positive pressure to the trachea, which was kept
constant at 5.5 cm H20, by means of an adjustable
Mediators of Inflammation" Vol 1992 255M. J. Post et al.
water seal connected with a T-piece to the inflation
tube. Thus, the end expiratory pressure was
constant, while the end inspiratory pressure rose as
a function of airway diameter. The area under the
end inspiratory pressure curve was measured and
expressed as a percentage of the area under the
(horizontal) curve representing the maximally
attainable end inspiratory pressure. Pulmonary
artery pressure and tracheal pressure were measured
by means of an Ailtech (MEDIO-E) and an
Elema-Sch6nander transducer, respectively. Each
pair of lungs was allowed to equilibrate for 15 min.
After antigen challenge, perfusate was continuously
collected for a period of 7 min and analysed for
mediators. In one series of experiments, designed
to study the influence of antigen challenge on
eicosanoid release, a triplet of 5 min perfusate
samples was collected: one before antigen chal-
lenge, a second from 1 to 6 min after antigen
challenge and a third from 10 to 15 min after
challenge.
Antigen challenge and drug treatment: Lungs were
challenged with a bolus injection of 0.2ml
(50/2g m1-1) undiluted TNP-OVA solution, into
the pulmonary artery. This proved to be a
supramaximal dose in previous studies.
All drugs were added to the perfusion fluid
during the entire course of the experiments starting
at least 15 min before antigen challenge. The drugs
were either dissolved in the perfusion fluid or added
to the infusion fluid by means of a constant infusion
just prior to the entrance into the pulmonary artery.
Determination of mediators: Histamine was measured
fluorometrically after pre-column derivatization
with 0-phthalaldehyde and subsequent separation by
means of HPLC. All eicosanoids were measured by
RIA. For this purpose, perfusate was collected in
1 min fractions, from 1 to 7 min after antigen
challenge. Each fraction was applied to a Sep-Pak
C18 cartridge. The cartridges had been prewashed
with ethanol, water and, finally, 0.5% EDTA in
water (pH 5.5). Prior to elution with 4ml
ethanol, the cartridges were flushed with 5 ml
water. [3H]-PGA2 was used as an internal standard
to determine recovery. Samples of 50 or 100/21
were dried and dissolved in RIA buffer. Detection
ranges were: 5-HETE (0-500 ng), 12-HETE
(0-1000 ng), 15-HETE (0-250 ng), PGE2
(0-1000 ng), 6k-PGF (0-250 ng), PGF2
(0-500 ng), TXB2 (0-250 ng), LTB4 (0-500 ng) and
peptidoleukotrienes (0-500 ng). The detection
limits for the prostaglandins, peptidoleukotrienes
and HETEs were 2, 5 and 10 pg respectively.
Cross reactivities for radioimmunoassays of LTs,
HETEs and prostaglandins (% at 50% B/B0) were
less than 1%, except for anti-5-HETE with LTB4
(4%), anti-PGF2 with 6k-PGFI (2.2%) and
anti-PGF2 with PGE2 (1.3%). The peptidoleuko-
trienes assay discriminates rather poorly between
LTC4, LTD4, LTE4 or LTF4, cross-reactivities
with these LTs being 55%, 100%, 51% and 67%
respectively.
Drugs and materials: Antisera and standards for RIAs
were obtained from Advanced Magnetics Inc.,
(Cambridge, MA, USA) and 3H-labelled antigen
from the Radiochemical Centre, (Amersham, UK).
Ovalbumin, grade V, was purchased from Sigma.
Trinitrobenzenesulphonic acid was obtained from
Baker Chem. (Deventer, The Netherlands). Sulma-
zole and milrinone were gifts from Dr Karl Thomae
GmbH (Biberach, Germany) and Sterling-Win-
throp (USA), respectively. AA 861 (2-12-hydroxy-
dodeca 5,10 dinyl) 3, 5, 6 trimethyl 1,4 benzo
quinone) was supplied by Takeda Chemical
Industries Ltd (Osaka, Japan). Theophylline,
salbutamol and isobutylmethylxanthine (IBMX)
were all purchased from Sigma. Sulmazole,
theophylline, salbutamol and IBMX were dissolved
in the perfusion medium, while milrinone and AA
861 were administered with an infusion to the
perfusion medium. For this purpose, milrinone was
dissolved in Krebs acidified with hydrochloric acid
to a pH of 4.5, not affecting the pH of the perfusion
fluid. AA 861 was dissolved in DMSO (final
concentration 0.3%). All constituents of the
perfusion fluid, ethanol and 0-phthalaldehyde were
obtained from Merck, and were of analytical grade.
Sep-Pak C18 cartridges were purchased from
Millipore Co.
Data anasis: In the text and figures, data represent
the arithmetic means +SE. Mediator release was
expressed as total amount present in the perfusate
collected from 1 to 7 min after challenge (yielding
45ml perfusate). Three control groups were
incorporated in this study, one matched with the
theophylline 10 and 100/IM, milrinone and
sulmazole treated groups, a second matched with
the theophylline 1 mM, IBMX and salbutamol
group and a third DMSO 0.3% control group. In
the second control group, time dependency of
mediator release was studied by collecting and
analysing 1 min fractions separately, again from 1
to 7 min after challenge. The sum of these fractions
were used for comparison with the drug treated
groups (theophylline 1 mM, IBMX, salbutamol).
Differences in mean bronchoconstriction and
mediator release were evaluated by means of a
one-way analysis of variance on raw data,
comparing the absolute figures from treated groups
with their respective control groups. If the F-test
showed significant differences between groups
(49 < 0.05), differences in means were evaluated
with Duncan’s multiple range test and judged to be
significant ifp < 0.05.
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Results
Time dependency of mediator release after antigen challenge"
(a) Preformed mediators. Antigen challenge in-
duced a rapid and substantial release of histamine
up to 857 105 ng min -1, n 7 (Fig. la). A total
of approximately 2 000 ng histamine was released
by each pair of lungs (weighing approximately 1 g).
Within 1 min after challenge, maximal concentra-
tions of histamine were measured. After 1 min
histamine release gradually subsided, reaching basal
release (227 43 ng min -1, n=7) in 7min. (b)
Eicosanoids. The mono-HETEs, 5-HETE, 12-
HETE and 15-HETE, were synthesized and
released by the rat isolated lung. Of these, the
release of 12-HETE was the most predominant
(Fig. l b). 15-HETE and 5-HETE were released
in small amounts only (_+ 500 pg min-) (Fig. lc).
PGI2, measured as 6k-PGF2 was the predominant
bronchorelaxant prostaglandin. Neither PGI2, nor
PGE2 showed a clear release pattern after antigen
stimulation (Fig. ld).
The bronchoconstrictive prostaglandin PGF2
and the stabile metabolite of thromboxane A2,
TXB2, were released in equal amounts (-+-1 000
pg min-) (Fig. l e). The release of TXB2 was
stimulated significantly at 2min after antigen
challenge, declining thereafter.
LTB4 and the peptidoleukotrienes, were released
in relatively small amounts by the rat lung (Fig. lf).
LTB4 showed a clear release pattern after antigen
stimulation reaching its maximum at t 3 min.
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FIG. 1. Release of mediators at various times after antigen challenge. Release of histamine (a), 12-HETE
(b), 5- and 15-HETE (c), PGE2 and 6k-PGFI (d), PGF2, and TXB2 (e), and the peptidoleukotrienes and
LTB4 (f). Antigen challenge was given at O. The data represent the means of six experiments, the bars
indicate the SE. Notice the different scales on the ordinates of each panel.
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Peptidoleukotriene release was also stimulated,
with a maximal release at t-- 4 min.
In four separate experiments, we attempted to
establish a release pattern for the peptidoleuko-
trienes, 12-HETE and TXB2, by collecting a triplet
of 5 min perfusate fractions. The results are shown
in Fig. 2. A stimulatory release pattern could be
observed for the peptidoleukotrienes and TXB2.
Antigen challenge in the rat lung did not stimulate
the release of 12-HETE and 6k-PGFI.
For all eicosanoids, antigen-induced synthesis
was low and in most instances undistinguishable
from basal release (Figs 1 and 2). In the
experiments where modulation of mediator release
by drugs was studied, total, i.e., basal and antigen
induced release, was measured.
Modulation of mono-HETE production by the drugs: The
mono-HETEs were quite uniformly aected by
theophylline, milrinone and sulmazole (Table 3).
These drugs reduced mono-HETE production at
high concentrations only, with the exception of
15-HETE, the production and release of which
seemed to be resistant to sulmazole. Salbutamol,
IBMX and AA 861 reduced 5-HETE, but not
12-HETE production.
Bronchoconstriction and total mediator release by antigen
challenged lungs: Table 1 lists the results of antigen
induced bronchoconstriction and total mediator
release in the three control groups (n 6). As
mentioned, we performed the experiments de-
scribed here in different seasonal periods and
therefore had two dierent control groups and one
vehicle control group. No significant differences in
mediator release between these groups were
observed, except for 5-HETE and LTB4. In control
group 2, PGE2 measurement failed.
Modulation of antigen induced bronchoconstriction and total
histamine release" In Table 2 the dose dependenl
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FIG. 2. Release patterns of peptidoleukotrienes (filled bars), 12-HETE
(12-HETE, coarse right-hatched bars), TXB2 (cross-hatched bars) and
6k-PGFI (6kPFI, fine right-hatched bars) when sensitized lungs are
challenged with antigen. Perfusate fractions were collected for 5 min
before antigen challenge, from to 6 min and from 10 to 15 min after
antigen challenge, represented in each cluster of bars by the first, second
and third bar, respectively. The data indicate the means _-+SE of four
experiments.
Table 1. Bronchoconstriction and mediator release in control
groups
Control Control 2 Control 3
(DMSO)
AUC (%) 32.0 + 3.8 28.9 _+ 4.8 30.7 _+ 4.8
Histamine (ng) 1774 _+ 178 2399 _+ 362 2294 _+ 437
5-HETE (ng) 3.0 _+ 0.4 4.7 ___
0.1 3.6 ___
0.6
12-HETE (ng) 26.4 _+ 2.1 25.6 _+ 1.4 26.9 + 6.2
15-HETE (ng) 1.2 _+ 0.1 1.8 __
0.3 1.5 + 0.4
PGE2 (ng) 22.6 _+ 5.4 ND 20.8 2.1
6k-PGFI (ng) 60 _+ 18 40 _+ 11 25.1 _+ 2.9
PGF2= (ng) 7.0 ___
2.0 7.5 _+ 1.0 5.9 __+ 0.9
TXB2 (ng) 5.4 _+ 0.6 5.7 ___
0.9 4.6 + 0.9
LTB4 (ng) 12.1 +_ 1.9 3.1 +_ 0.8* 11.6 +_ 1.4
PLTs (ng) 3.5 _+ 0.2 4.8 _+ 1.0 2.9 _+ 0.4
Control groups were studied at different periods. Although the
lungs were challenged with antigen, total (antigen induced and
basal) mediator release is depicted (means ___
SE). The asterisks
indicate values that are significantly different from the values in
the other two groups (p < 0.05, n 6). ND" not determined.
AUC: area under curve, bronchoconstriction" PLTs" peptido-
leukotrienes.
inhibition of antigen induced bronchoconstriction
by theophylline, milrinone, sulmazole, IBMX and
salbutamol is depicted. AA 861 at a concentration
of 5/aM did not affect antigen induced bronchocon-
striction. Histamine release was rather insensitive to
the action of various drugs. Only sulmazole at a
concentration of 100/aM, reduced the release of this
autocoid (Table 2). Theophylline 1 mM was not
Table 2. Modulation of total histamine release and antigen
induced bronchoconstriction
AUC (%) HR (%)
Theophylline
0.01 mM 24+13" -5+25
0.1 mM 29 + 12" 27 + 19
mM 73 + 6** ND
Milrinone
0.01 mM 25-t- 11 -2 -t- 16
0.1 mM 50 + 8** 21 + 18
Sulmazole
0.01 mM 31 + 10" 31 + 10
0.1 mM 72 + 5* 33 + 10"
IBMX
10/,M 54 _+ 8** 12 _+ 15
Salbutamol
#M 11 _+18 8_+14
10/M 36 _+ 10" 15 _+ 16
AA 861
5 /M 13 _+ 11 21 _+ 10
Data are expressed as percentage inhibition of control data of
bronchoconstriction and histamine release as given in Table 1,
and represent means _+ SEM, n 6 for all (the SEM is calculated
from the variances of both the control and the treated values).
The asterisks indicate significance of difference with controls at
p < 0.05 or, if double, at p < 0.01. AUC: area under curve’ HR"
histamine release; ND" not determined.
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Table 3. Modulation of total eicosanoid release
5- H ETE 12- H ETE 15-H ETE PGE2 6PG F1 PGF2 TXB2 LTB4 pepLT
Theophylline
0.01 mM 0 7+12 12_+13 79+8" 61 ___16" 27+24 +17 24+13 0
0.1 mM 7_+20 3+13 29+7" 86+5" 80+6" 49+15" 22+_17 43+13" 0
mM 78 __+ 3* 40 __+ 12* 83 _-_+ 6* ND 75 7* 62 _+ 6* 74 -I- 5* 82 -t- 8* 87 ___
4*
Milrinone
0.01 mM 0 23 + 11 17 + 13 82 + 7* 80 + 7* 47 +__ 15" 34 + 11" 29 -I- 19 0
0.1 mM 31 + 11 29 _+ 8* 37 -t- 12* 86 + 8* 80 + 6* 54 _+ 14" 76 + 5* 66 _+ 7* 35 -I- 5*
Sulmazole
0.01 mM 28 + 14 6 _+ 10 26 + 9 56 + 22* 74 _+ 10" 51 + 16" 35 -I- 8* 44 _+ 12" 22 _+ 12
0.1 mM 52 + 7* 53 5* 26 + 15 95 _+ 4* 87 + 5* 82 + 5* 89 3* 83 ___
4* 51 9*
Salbutamol
/M 66 _+ 2* 36 _+ 13 ND ND 58 _+ 13" 67 ___
7* 64 _+ 10" 32 +_ 20 78 +_ 6*
10 #M 57 +_ 5* ND ND ND 66 _+ 10" 66 _+ 5* 56 ___
13* 20 +_ 33 73 ___
9*
IBMX
10 #M 76 +_ 2* 6 +_ 21 ND ND 81 +_ 5* 67 _+ 5* 59 +_ 8* 48 ___
19* 70 _+ 6*
AA 861
5/M 65 _+ 9* 4 _+ 25 65 _+ 10* 90 ___
3** 30 _+ 19 43 _+ 12* 20 _+ 21 99 +_ 2** 73 +_ 3**
Data are expressed as percentage inhibition of control data of bronchoconstriction and mediator release as given in Table
(theophylline 0.01 and 0.1 mM, milrinone and sulmazole, control 1" theophylline mM, salbutamol and IBMX, control 2’
AA 861, control 3) and represent means -I-SE (the SE is calculated from the variances of control and treated values). The
asterisks indicate significant differences with controls at p<0.05 or, if double, at p<0.01. One-way analysis of
variance was performed on raw data, not on percentages. ’0’ is entered whenever the calculated percentage of inhibition was
negative, without being significantly different from zero. In no case was a potentiation of arachidonic acid metabolism
observed. N D" not determined.
evaluated, since the aminophylline used for these
high concentrations interfered with the fluoro-
metric detection of histamine.
Modulation of bronchorelaxant prostaglandins The produc-
tion of the bronchorelaxant prostaglandin 6k-PGFI
was inhibited by five of the six drugs tested. AA
861 had no eflect (Table 3). For sulmazole,
salbutamol and theophylline obvious dose de-
pendency was observed, while milrinone apparently
had reached its maximal effect at 0.01 mM. PGE2
showed a pattern similar to 6k-PGFI. Since PGE2
data fail in the second control group, the effect of
theophylline 1 mM, IBMX, salbutamol could not
be calculated. However, in absolute figures, the
amounts of PGE2 were comparable to the other
treated groups, ranging from 1.7 to 5.3 ng, as
opposed to 22.6 ng in control group 1 (Table 2).
Surprisingly, PGE2 production was strongly
reduced in the AA 861 treated group.
Modulation ofbronchoconstrictive prostaglandins Production
of PGF2 and TXB2 was effectively reduced by all
cAMP mediated drugs (Table 3). For theophylline,
milrinone and sulmazole a dose dependency was
observed. Increasing the dose of salbutamol from
1 to 10/M had no additional effect on leukotriene
production. AA 861 caused a moderate reduction
of PGF2, leaving TXB2 synthesis unaffected.
Modulation of leukotriene production: Synthesis of LTB4
and the peptidoleukotrienes were reduced by
theophylline and milrinone at high concentrations.
Sulmazole and IBMX already at 0.01 mM reduced
LTB4 production significantly (Table 3). AA 861
almost abolished LTB4 and peptidoleukotriene
synthesis. In contrast, salbutamol had no at:fect on
LTB4 synthesis.
Discussion
In this paper we confirmed and extended earlier
observations on the reduction of synthesis and
release of peptidoleukotrienes by milrinone, sulma-
zole and theophylline in the rat isolated lung.
Rossing and coworkers
6 postulated a selective
induction of bronchorelaxant prostaglandins by
milrinone to explain the inhibition of milrinone
induced bronchorelaxation by indomethacin. How-
ever, our data show that these and other supposedly
cAMP mediated drugs reduce arachidonic acid
metabolism in a global rather than a differential
manner.
Global reduction of arachidonic acid metabolism
by cAMP mediated drugs suggests interference
with an early stage of arachidonic acid metabolism
prior to separation into the lipoxygenase and
cyclooxygenase pathway. This might be explained
by an evaluation of intracellular cAMP reducing the
release of arachidonic acid from the phospholipid
pool. It has been shown for instance that beta
agonists, by stimulation of adenylate cyclase, reduce
phospholipase A2 activity and the subsequent
release of arachidonic acid metabolites.9’1
In accordance with other reports, histamine
release was not affected by the drugs tested,s’’2
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Apparently, production of histamine release is less
susceptible to elevation of cAMP than eicosanoid
production.
9,13
For theophylline, milrinone and sulmazole,
mechanisms of action other than cAMP elevation
have been proposed. Antagonism of adenosine
receptors is the most strongly advocated alternative.
On the basis of previous experiments we argued
against adenosine antagonism as a likely mechanism
of action for milrinone and sulmazole in the
concentrations used in this study.
14
Milrinone is a selective inhibitor of the
phosphodiesterase enzyme complex III, which
hydrolyses mainly cAMP. Whether this selectivity
still holds in the rat lung for concentrations of 0.01
to 0.1 mM is uncertain. In view of the similarity of
the pharmacological profiles of theophylline,
IBMX, sulmazole and theophylline it is likely that
nonselective inhibition of the cyclic nucleotide
phosphodiesterase isozyme complex is responsible
for the observed effects.
Using RIA, a wide spectrum of eicosanoids could
be measured in the perfusate of the isolated rat
lungs, comprising major representatives of the two
most important pathways of arachidonic acid
metabolism. Of the mono-HETEs, 12-HETE was
the most predominant, whereas only small amounts
of 15- and 5-HETE were produced. The same holds
for guinea-pigs, whereas in man, 15-HETE
production is more pronounced.
15 The quantities of
arachidonic acid metabolites measured in our
experiments, are largely correlated with those found
in rat mast cells, human lung parenchyma and the
guinea-pig isolated lung.
15-17 TXB2 and leuko-
trienes however seem to be more prominent in the
guinea-pig than in the rat. The production of
histamine, TXB2, LTB4 and the peptidoleuko-
trienes was stimulated by a.ntigen, as was also
shown by Turner and Dollery (1988), using the
isolated guinea-pig lung.
18 In contrast, no clear
stimulation of 6k-PGFI, PGF2, PGE2 and the
mono-HETEs was observed in our study. Thus, it
is likely that in this model the release of
mono-HETEs and prostaglandins is mainly basal.
Whether this reflects a constant low-level stimula-
tion of the isolated lung is unknown. The reduction
of eicosanoid release by drugs shows the
reversibility of eicosanoid release in this model,
ruling out leakage of eicosanoids from damaged
cells.
AA 861 was introduced in this study to validate
the study design. A partial selectivity in reducing
arachidonic acid metabolism could indeed be
demonstrated. As expected, AA 861 caused an
almost complete cessation of leukotriene produc-
tion in our experiments, while thromboxane and
PGI2 remained unaffected. However, the produc-
tion of 15-HETE, PGF2 and PGE2 was reduced
as well. In contrast, at AA 861 concentrations up
to 10/,M, no inhibition of human platelet
cyclooxygenase or PGE2 production by mouse
myocardial cells was observed in other studies. 8’19
Recently it became clear that AA 861 was not
selective under all conditions and in all animal
strains.2’2 In human mast cells from the skin and
the lung for instance, AA 861 potently inhibited
anti-IgE induced PGD2 release.
22 The selectivity of
this agent obviously needs further documentation.
Antigen induced production of leukotrienes and
other eicosanoids is probably not directly respon-
sible for early antigen induced bronchoconstriction.
The drugs tested in this study reduced bronchocon-
striction at concentrations that were inadequate for
inhibition of leukotriene production. A similar
observation has been made for forskolin.
23 In view
of these data, our finding that AA 861 had no effect
on bronchoconstriction, while almost abolishing
leukotriene production, supports the prevailing
notion that leukotrienes have little significance in
early anaphylactic bronchoconstriction in the
rat.24,25
In conclusion, all cAMP mediated drugs reduced
antigen induced bronchoconstriction and the
production of eicosanoids in isolated rat lungs.
Arachidonic acid metabolism is impeded at a site
proximal to the separation into lipoxygenase and
cyclooxygenase pathways. Whether differences in
this respect exist between phosphodiesterase
inhibitors and stimulators of adenylate cyclase,
remains to be established. The results with AA 861
show that immediate antigen induced bronchocon-
striction is not mediated by leukotrienes. Finally,
we suggest that AA 861 might not in all conditions
be a selective 5-1ipoxygenase inhibitor.
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